Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_assertion type Assertion NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_head.
- NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_assertion description "[The distribution of the treatment-related MDS cases was different than 'de novo' MDS with a high percentage of RAEB-T, and with the treatment related AMLs, there were a higher percentage of patients with FAB M6 (erythroleukemia), and no cases of FAB M3 (hypergranular promyelocytic).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_provenance.
- NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_assertion evidence source_evidence_literature NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_provenance.
- NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_assertion SIO_000772 3504435 NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_provenance.
- NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_assertion wasDerivedFrom befree-20150227 NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_provenance.
- NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_assertion wasGeneratedBy ECO_0000203 NP913990.RAOA383X_EO81n57hooTwgklRKHYqx2-KSnuWBYmzppG0130_provenance.